CORC

在结果中检索

CORC

浏览/检索结果: 共29条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
BRCANet: A deep hybrid network in predicting BRCA1/2 gene mutation of breast cancer with dynamic contrast-enhanced breast MRI. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Cao, Wen-Ming;  Wang, Xiaojia;  Liu, Jian;  Wang, Lili;  Zhang, Xiaodong
收藏  |  浏览/下载：13/0  |  提交时间：2022/12/23
天琴计划简介 期刊论文
中山大学学报(自然科学版)/Acta Scientiarum Naturalium Universitatis Sunyatseni, 2021, 卷号: 60, 期号: 1-2, 页码: 1-19
作者:  罗俊;  艾凌皓;  艾艳丽;  安子聪;  白伟钢
收藏  |  浏览/下载：138/0  |  提交时间：2021/01/18
Effect of superplasticisers and their mechanisms of action on magnesium oxysulfate cement properties 期刊论文
ADVANCES IN CEMENT RESEARCH, 2020, 卷号: 32, 期号: 5, 页码: 225-233
作者:  Chen, Cong;  Wu, Chengyou;  Zhang, Huifang;  Chen, Yuanji;  Niu, Jiazhen
收藏  |  浏览/下载：27/0  |  提交时间：2021/11/16
THE EFFECTS OF CALCIUM AND POTASSIUM DIHYDROGEN PHOSPHATE ON THE PROPERTIES OF MAGNESIUM OXYSULFATE CEMENTS 期刊论文
CERAMICS-SILIKATY, 2020, 卷号: 64, 期号: 1, 页码: 7-17
作者:  Luo, Kejia;  Wu, Chengyou;  Li, Zhen;  Liu, Panpan;  Pang, Ruiyang
收藏  |  浏览/下载：27/0  |  提交时间：2021/11/16
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：35/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace